Abnormal uterine bleeding: A focus on polycystic ovary syndrome

Women's Health

Volumn 5, Issue 3, 2009, Pages 313-324

  Hickey, Martha ^a   Karthigasu, Krish ^a   Agarwal, Sweta ^b  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b PIVET Medical Centre   (Australia)

Author keywords

Abnormal uterine bleeding; Adolescents; Dysfunctional uterine bleeding; Hormonal therapy; Menstrual irregularities; Oral contraceptive pill; Perimenopausal; Polycystic ovarian syndrome; Progestogens; Reproductive age

Indexed keywords

ESTROGEN; ETHINYLESTRADIOL; FOLLITROPIN; GESTAGEN; GLUCOSE; IRON; LEVONORGESTREL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROLACTIN; TESTOSTERONE; THYROTROPIN;

ACANTHOSIS; ACNE; ADOLESCENT HEALTH; AGE DISTRIBUTION; ALOPECIA; ANEMIA; BLOOD CELL COUNT; BODY MASS; CLINICAL FEATURE; CYTOLOGY; DIET SUPPLEMENTATION; ENDOMETRIUM BIOPSY; FOLLITROPIN BLOOD LEVEL; GALACTORRHEA; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIRSUTISM; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; IRON THERAPY; LUTEINIZING HORMONE BLOOD LEVEL; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY POLYCYSTIC DISEASE; PREGNANCY TEST; PROLACTIN BLOOD LEVEL; RECURRENT DISEASE; REVIEW; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY; ADOLESCENT; ADULT; AGE; CHILD; ECONOMICS; FEMALE; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTOR; UTERUS BLEEDING;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; FEMALE; HUMANS; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTORS; UTERINE HEMORRHAGE; YOUNG ADULT;

EID: 67651160735     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.20     Document Type: Review

References (69)

1. University of Leeds, Nuffield Institute for Health, NHS centre for reviews and dissemination: The management of menorrhagia: what are effective ways of treating excessive regular menstrual blood loss in primary and secondary care? Effective Health Care 9, 1-14 (1995).
2. Awwad JT, Toth TL, Schiff I: Abnormal uterine bleeding in the perimenopause. Int. J. Fertil. 38, 261 (1993).
3. Shapley M, Jordan K, Croft PR: An epidemiological survey of symptoms of menstrual loss in the community. Br. J. Gen. Pract. 54, 359-363 (2004).
4. Treolar AE, Boynton RE, Behn BG, Brown BW: Variation of the human menstrual cycle through reproductive life. Int. J. Fertil. 12(1), 77-126 (1970).
5. Fraser IS, Critchley HO, Munro MG, Broder MA: Process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil. Steril. 87, 466-476 (2007).
6. Spilsbury K, Semmens JB, Hammond I, Bolck A: Persistent high rates of hysterectomy in Western Australia: a population-based study of 83 000 procedures over 23 years. BJOG 113, 804-809 (2006).
7. Fraser IS: Menorrhagia: a pragmatic approach to the understanding of causes and the need for investigations. Br. J. Obstet. Gynecol. 101, 3-7 (1994).
8. Spence JE: Anovulation and monophasic cycles. Ann. NY Acad. Sci. 16, 173-176 (1997).
9. Bravender T, Emans SJ: Menstrual disorders. Dysfunctional uterine bleeding. Pediatr. Clin. North Am. 46, 545-553 (1999).
10. Group REA-SPCW: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81, 19-25 (2004).
11. Homburg R, Lambalk CB: Polycystic ovary syndrome in adolescence - a therapeutic conundrum. Hum. Reprod. 19, 1039-1042, (2004).
12. Venturoli S, Porcu E, Fabbri R et al.: Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr. Res. 38, 974-980, (1995).
13. van Hooff MH, Voorhorst FJ, Kaptein MB et al.: Predictive values of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at aged 15 years for oligo-amenorrhoea at aged 18 years. Hum. Reprod. 19, 383-392 (2004).
14. Koutras DA: Disturbances of menstruation in thyroid disease. Ann. NY Acad. Sci. 816, 280-284 (1997).
15. Minjarez DA: Abnormal bleeding in adolescents. Semin. Reprod. Med. 21, 363-373 (2003).
16. Krettek JE, Arkin SI, Chaisilwattana P et al.: Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting. Obstet. Gynecol. 81, 728-731 (1993).
17. Emans, SJ: Dysfunctional uterine bleeding In: Pediatric and Adolescent Gynecology. Emans SJ, Laufer MR, Goldstein DP (Eds). Lippincott Williams & Wilkins, PA, USA 270 (2005).
18. Mitan LA, Slap GB: Adolescent menstrual disorders. Update. Med. Clin. North Am. 84, 851-868 (2000).
19. Bayer SR, DeCherney AH: Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA 269, 1823-1828 (1993).
20. Welt CK, Smith PC, Taylor AE: Evidence of early ovarian aging in fragile X premutation carriers. J. Clin. Endocrinol. Metab. 89, 4569-4574 (2004).
21. Balen AH, Laven JS, Tan SL, Dewailly D: Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum. Reprod. Update 9, 505-514 (2003).
22. Lavin C: Dysfunctional uterine bleeding in adolescents. Curr. Opin. Pediatr. 8, 328-332(1996).
23. Strickland JL, Wall JW: Abnormal uterine bleeding in adolescents. Obstet. Gynecol. Clin. North Am. 30, 321-335 (2003).
24. Claessens EA, Cowell CA: Acute adolescent menorrhagia. Am. J. Obstet. Gynecol. 139, 277-280, (1981).
25. Ibanez L, Zegher F: Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J. Clin. Endocrinol. Metab. 90, 39-43, (2005).
26. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L: Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J. Adolesc. Health 29, 160-169, (2001).
27. Ryan MJ, Aydin A: Fragile X and reproduction. Curr. Opin. Obstet. Gynecol. 20, 216-220, (2008).
28. Deplewski D, Rosenfield RL: Role of hormones in pilosebaceous unit development. Endocr. Rev. 21, 363-392(2000).
29. Buggs C, Rosenfield R: Polycystic ovary syndrome in adolescence. Endocrinol. Metab. Clin. N. Am. 34, 677-705 (2005).
30. Futterweit W, Deligdisch L: Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J. Clin. Endocrinol. Metab. 62, 16-21 (1986).
31. Vandenbroucke JP, Rosing J, Bloemenkamp KW et al.: Medical progress: oral contraceptives and the risk of venous thrombosis. N. Engl. J. Med. 344, 1527-1535 (2001).
32. Venn A, Bruinsma F, Werther G et al.: Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 364, 1513-1518 (2004).
33. Nader S, Diamanti-Kandaris E: Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Human Reprod. 22, 317-322 (2007).
34. Farquhar, CM, Lethaby A, Sowter M et al.: An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am. J. Obstet. Gynecol. 181, 525-529 (1999).
35. Farhi DC, Nosanchuk J, Silverberg SG: Endometrial adenocarcinoma in women under 25 years of age. Obstet. Gynecol. 68, 741-745(1986).
36. Azziz R, Woods KS, Reyna R et al.: The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745-2749 (2004).
37. Wilansky DL, Greisman B: Early hypothyroidism in patients with menorrhagia. Am. J. Obstet. Gynecol. 160, 673(1989).
38. Ridgway EC, Maloof F, Longcope C: Androgens and oestrogen dynamics in hyperthyroidism. J. Endocrinol. 95, 105-115 (1982).
39. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD et al.: Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J. Clin. Endocrinol. Metab. 83, 3083-3088 (1998).
40. Long CA: Evaluation of patients with abnormal uterine bleeding. Am. J. Obstet. Gynecol. 175, 784-786(1996).
41. Goldstein SR, Zeltser I, Horan CK et al.: Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am. J. Obstet. Gynecol. 177, 102-108 (1997).
42. Chuong CJ, Brenner PF: Management of abnormal uterine bleeding. Am. J. Obstet. Gynecol. 175, 787-792 (1996).
43. Hickey M, Higham J, Fraser IS: Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane review (4), CD001895 (2007).
44. Futterweit W: Polycystic ovary syndrome: a common reproductive and metabolic disorder necessitating early recognition and treatment. Prim. Care 34, 761-789 (2007).
45. Druckman R: Long-term use of progestogens - getting the balance right: molecular biology and the endometrium. Gynecol. Enocrinol. (Suppl. 1), 53-61 (2007).
46. Schindler AE, Campagnoli C, Druckmann R et al.: Classification and pharmacology of progestins. Maturitas 46(Suppl. 1), S7-S16 (2003).
47. Guido M, Romualdi D, Giuliani M: Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J. Clin. Endocrinol. Metab. 89, 2817-2823 (2004).
48. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ et al.: A modern medical quandary: polycystic ovary syndrome, insulin resistance and oral contraceptive pills. J. Clin. Endocrinol. Metab. 88, 1927-1932 (2003).
49. Baillargeon JP, McClish DK, Essah PA et al.: Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 3863-3870 (2005).
50. Cagnacci A, Paoletti AM, Renzi A et al.: Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J. Clin. Endocrinol. Metab. 88, 3621-3625 (2003).
51. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO: Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum. Reprod. 13, 2706 (1998).
52. Santoro N: The menopause transition: an update. Hum. Reprod. Update 8, 155-160 (2002).
53. Van Voorhis BJ, Santoro N, Harlow S, Crawford SL, Randolf J: The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet. Gynecol. 112, 101-108 (2008).
54. Burger HG, Robertson DM, Baksheev L et al.: The relationship between the endocrine characteristics and the regularity of menstrual cycles in the approach to menopause. Menopause 12, 267-274 (2005).
55. Dibi RP, Zettler CG, Pessini SA et al.: Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer. Menopause 16(2) 293-300 (2009)
56. Brand A, Dubuc-Lissoir J, Ehlen Y, Plante M: Diagnosis of endometrial cancer in women with abnormal vaginal bleeding. SOGC Clin. Pract. Guidelines 8, 1-3 (2008).
57. Maheux R: The forties. Menopause 12, 246-247 (2005).
58. Guido RS, Kanbour-Shakir A, Rulin MC, Christopherson WA: Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer. J. Reprod. Med. 40, 553-555 (1995).
59. Chuong CJ, Brenner PF: Management of abnormal uterine bleeding. Am. J. Obstet. Gynecol. 175, 787- 792, (1996).
60. Perrot N, Frey I, Bigot JM: Ultrasono hysterography: technique and indications. J. Radiol. 77, 687-690 (1996).
61. de Kroon CD, de Bock GH, Dieben SW, Jansen FW: Saline contrast hysterosonography in abnormal uterine bleeding: a systematic review and meta-ana lysis. BJOG 110, 938-947 (2003).
62. Mortakis AK, Mavrelos K: Transvaginal ultrasonography and hysteroscopy in the diagnosis of endometrial abnormalities. J. Am. Assoc. Gynecol. Laparosc. 4, 449-452 (1997).
63. van Dongen H, de Kroon CD, Jacobi CE, Trimbos JB, Jansen FW: Diagnostic hysteroscopy in abnormal uterine bleeding: a systematic review and meta-ana lysis. BJOG 114, 664-675 (2007).
64. Albers JR, Hull SK, Wesley RM: Abnormal uterine bleeding. Am. Fam. Physician. 69, 1915-1926 (2004).
65. Hidalgo M, Bahamondes L, Perrotti M et al.: Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contracetion 65, 129-132 (2002).
66. Hampton NR, Rees MC, Lowe DG et al.: Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum. Reprod. 20, 2653- 2660 (2005).
67. Dickersin K, Munro M, Langenberg P et al.: Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet. Gynecol. 110, 1279-1289 (2007).
68. Marsh FA, Bekker HB, Duffy SA: A survey of women's views of Thermachoice endometrial ablation in the outpatient versus day case setting. Br. J. Obstet. Gynaecol. 115, 31-37 (2008).
69. Amso NN, Fernandez H, Vilos G: Uterine endometrial thermal balloon therapy for the treatment of menorrhagia: long-term multicentre follow-up study. Humanit. Rep. 18, 1082-1087 (2003).